Mesoblast, which is developing regenerative medicine based on adult stem cells, raised $60 million by offering 7.5 million ADSs at $8, well below the expected $12.10 price. Mesoblast plans to list on the Nasdaq under the symbol MESO. J.P. Morgan and Credit Suisse acted as lead managers on the deal.
